MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling

Stock Information for Medipharm Labs Corp

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Medipharm Labs Corp

MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
MediPharm Labs to Enter New Market with Costa Rica Supply Agreement
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns
MediPharm Labs Completes First Shipment to France
MediPharm Announces Complete Dismissal of Defamation Action Initiated by Apollo, Nobul and Regan McGee Under Ontario Anti-SLAPP Law

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.